Cantor Fitzgerald Starts Glycomimetics (GLYC) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts GLYC Hot Sheet
Price: $0.16 --0%
Rating Summary:
6 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 2
Rating Summary:
6 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 2
Join SI Premium – FREE
Cantor Fitzgerald initiates coverage on Glycomimetics (NASDAQ: GLYC) with a Overweight rating.
For an analyst ratings summary and ratings history on Glycomimetics click here. For more ratings news on Glycomimetics click here.
Shares of Glycomimetics closed at $0.27 yesterday.
You May Also Be Interested In
- Citi initiates ATI Inc. coverage with Buy rating, $229 target
- HSBC Starts Sigenergy Technology (6656:HK) at Buy
- CLSA Starts Busy Ming Group (1768:HK) at Outperform (2)
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
